source
- Revolution Medicines' Rasonge receives second-line pancreatic cancer nod, could drive $2.3B sales by 2028Revolution Medicines announced that its RAS inhibitor Rasonge earned a second-line indication for pancreatic ductal adenocarcinoma, marking the first regulatory step in the company's PDAC strategy.…
- Moderna and Merck report late-stage success for personalized mRNA cancer vaccineModerna and Merck announced that their personalized cancer vaccine achieved its primary goals in a late-stage clinical trial, sparking enthusiasm across the biotech community. The experimental the…